Abstract

To fight the Covid-19 pandemic caused by the RNA virus SARS-CoV-2 a global vaccination campaign is in progress to achieve the immunization of billions of people mainly with adenoviral vector- or mRNA-based vaccines, all of which encode the SARS-CoV-2 Spike protein. In some rare cases, cerebral venous sinus thromboses (CVST) have been reported as a severe side effect occurring 4 to 14 days after the first vaccination and were often accompanied by thrombocytopenia. Besides CVST, splanchnic vein thromboses (SVT) and other thromboembolic events have been observed. These events only occurred following vaccination with adenoviral vector-based vaccines but not following vaccination with mRNA-based vaccines. Meanwhile, scientists have proposed an immune-based pathomechanism and the condition has been coined Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT). Here, we describe an unexpected mechanism that could explain thromboembolic events occurring with DNA-based but not with RNA-based vaccines. We show that DNA-encoded mRNA coding for Spike protein can be spliced in a way that the transmembrane anchor of Spike is lost, so that nearly full-length Spike is secreted from cells. Secreted Spike variants could potentially initiate severe side effects when binding to cells via the ACE2 receptor. Avoiding such splicing events should become part of a rational vaccine design to increase safety of prospective vaccines.

Data availability

The original WUHAN SARS-CoV-2 sequence is available in the NCBI database (NCBI Reference Sequence: NC_045512.2); the adenoviral and codon-optimized Spike sequence data have a protected intellectual property by the companies. The primary sequence of Ad5.S, designed and used by the colleagues in Ulm, can be retrieved upon request (contact Prof. Stefan Kochanek).

The following previously published data sets were used

Article and author information

Author details

  1. Eric Kowarz

    Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Lea Krutzke

    Department of Gene Therapy, University of Ulm, Ulm, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4092-4131
  3. Marius Külp

    Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Patrick Streb

    Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Patrizia Larghero

    Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Jennifer Reis

    Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Silvia Bracharz

    Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Tatjana Engler

    Department of Gene Therapy, University of Ulm, Ulm, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Stefan Kochanek

    Department of Gene Therapy, University of Ulm, Ulm, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Rolf Marschalek

    Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany
    For correspondence
    Rolf.Marschalek@em.uni-frankfurt.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4870-3445

Funding

Goethe University Corona Task Force

  • Rolf Marschalek

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2022, Kowarz et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 10,912
    views
  • 790
    downloads
  • 49
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Eric Kowarz
  2. Lea Krutzke
  3. Marius Külp
  4. Patrick Streb
  5. Patrizia Larghero
  6. Jennifer Reis
  7. Silvia Bracharz
  8. Tatjana Engler
  9. Stefan Kochanek
  10. Rolf Marschalek
(2022)
Vaccine-induced COVID-19 mimicry syndrome
eLife 11:e74974.
https://doi.org/10.7554/eLife.74974

Share this article

https://doi.org/10.7554/eLife.74974

Further reading

    1. Cell Biology
    2. Plant Biology
    Baihong Zhang, Shuqin Huang ... Wenli Chen
    Research Article

    Autophagy-related gene 6 (ATG6) plays a crucial role in plant immunity. Nonexpressor of pathogenesis-related genes 1 (NPR1) acts as a signaling hub of plant immunity. However, the relationship between ATG6 and NPR1 is unclear. Here, we find that ATG6 directly interacts with NPR1. ATG6 overexpression significantly increased nuclear accumulation of NPR1. Furthermore, we demonstrate that ATG6 increases NPR1 protein levels and improves its stability. Interestingly, ATG6 promotes the formation of SINCs (SA-induced NPR1 condensates)-like condensates. Additionally, ATG6 and NPR1 synergistically promote the expression of pathogenesis-related genes. Further results showed that silencing ATG6 in NPR1-GFP exacerbates Pst DC3000/avrRps4 infection, while double overexpression of ATG6 and NPR1 synergistically inhibits Pst DC3000/avrRps4 infection. In summary, our findings unveil an interplay of NPR1 with ATG6 and elucidate important molecular mechanisms for enhancing plant immunity.

    1. Cell Biology
    Chengfang Pan, Ying Liu ... Changlong Hu
    Research Article

    Prostaglandin E2 (PGE2) is an endogenous inhibitor of glucose-stimulated insulin secretion (GSIS) and plays an important role in pancreatic β-cell dysfunction in type 2 diabetes mellitus (T2DM). This study aimed to explore the underlying mechanism by which PGE2 inhibits GSIS. Our results showed that PGE2 inhibited Kv2.2 channels via increasing PKA activity in HEK293T cells overexpressed with Kv2.2 channels. Point mutation analysis demonstrated that S448 residue was responsible for the PKA-dependent modulation of Kv2.2. Furthermore, the inhibitory effect of PGE2 on Kv2.2 was blocked by EP2/4 receptor antagonists, while mimicked by EP2/4 receptor agonists. The immune fluorescence results showed that EP1–4 receptors are expressed in both mouse and human β-cells. In INS-1(832/13) β-cells, PGE2 inhibited voltage-gated potassium currents and electrical activity through EP2/4 receptors and Kv2.2 channels. Knockdown of Kcnb2 reduced the action potential firing frequency and alleviated the inhibition of PGE2 on GSIS in INS-1(832/13) β-cells. PGE2 impaired glucose tolerance in wild-type mice but did not alter glucose tolerance in Kcnb2 knockout mice. Knockout of Kcnb2 reduced electrical activity, GSIS and abrogated the inhibition of PGE2 on GSIS in mouse islets. In conclusion, we have demonstrated that PGE2 inhibits GSIS in pancreatic β-cells through the EP2/4-Kv2.2 signaling pathway. The findings highlight the significant role of Kv2.2 channels in the regulation of β-cell repetitive firing and insulin secretion, and contribute to the understanding of the molecular basis of β-cell dysfunction in diabetes.